Mitigating adverse effects of antiseizure medications in pediatric drug-resistant epilepsy: an open-label single-arm study of adjunctive Epilamba®

Background Managing the adverse effects associated with anti-seizure medications is essential for enhancing the quality of life and adherence to treatment in children with drug-resistant epilepsy. This study evaluated the potential of Epilamba®, a natural supplement, in mitigating treatment-related adverse effects. Methods Pediatric patients with drug-resistant epilepsy on polytherapy were enrolled to receive adjunctive Epilamba® (1 sachet/day) for six months. Assessments of seizure frequency, systemic and neurological toxicity, and gastrointestinal symptoms were conducted using standardized questionnaires at baseline (T0), three months (T1), and six months (T2). Data were analyzed using the Wilcoxon signed-rank test, with significance set at p